drugset / Trial / NCT01513850

A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients

NCT01513850

Phase 3 Completed 87 enrolled SK Chemicals Co., Ltd.
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to Evaluate the efficacy and safety of Hepabulin IV (HBIG, a study drug) after liver transplantation.

Timeline

Start
2010-10
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject hepatitis B immune globulin Protein / enzyme biologic Intravenous